Peter Gray - Jazz Pharmaceuticals Non-Executive Director
| J7Z Stock | EUR 102.50 0.80 0.77% |
Director
Mr. Peter Gray is an Independent Director of Jazz Pharmaceuticals PLC. Mr. Gray currently serves as Chairman of the board of directors of UDG Healthcare plc, an international provider of healthcare services. He is also Chairman of two privatelyheld companies providing outsourced services to the biopharma industry and Chairman of a nonprofit educational establishment. In September 2011, Mr. Gray retired from his position as Chief Executive Officer of ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, which he held since November 2002. At ICON plc, Mr. Gray previously served as Group Chief Operating Officer from June 2001 to November 2002 and Chief Financial Officer from June 1997 to June 2001. From November 1983 to November 1989, Mr. Gray served as senior financial officer at Elan Corporation plc, a pharmaceutical company since 2013.
| Age | 63 |
| Tenure | 11 years |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Peter Gray Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Gray against Jazz Pharmaceuticals stock is an integral part of due diligence when investing in Jazz Pharmaceuticals. Peter Gray insider activity provides valuable insight into whether Jazz Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Jazz Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jazz Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Gray over a week ago Acquisition by Peter Gray of 28 shares of Lands End subject to Rule 16b-3 |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO, Senior Vice President | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Non-Executive Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, Ex CFO | ||
| Robert MD, Ex RD | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Vice President - Finance, Principal Accounting Officer | ||
| Seamus Mulligan, Independent Director | ||
| Russell Cox, Chief Commercial Officer, Executive Vice President | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Ex Officer | ||
| George Eliades, Sr Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, President COO | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive Vice President General Counsel | ||
| Patricia Carr, VP Officer | ||
| Heather McSharry, Director | ||
| Michael Miller, Senior Vice President - U.S. Commercial | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Norbert Riedel, Director | ||
| Catherine Sohn, Director | ||
| Heidi Manna, VP Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jazz Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jazz Pharmaceuticals' short interest history, or implied volatility extrapolated from Jazz Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |